Tacrolimus decreases the expression of eotaxin, CCR3, RANTES and interleukin-5 in atopic dermatitis

C.W. Park

Departments of Dermatology and Pathology, Kang-Nam Sacred Heart Hospital, College of Medicine, Hallym University, 948-1 Daelim 1-dong, Youngdeungpo-Gu, Seoul 150-950, Korea

Search for more papers by this author

B.H. Lee,

B.H. Lee

Departments of Dermatology and Pathology, Kang-Nam Sacred Heart Hospital, College of Medicine, Hallym University, 948-1 Daelim 1-dong, Youngdeungpo-Gu, Seoul 150-950, Korea

Search for more papers by this author

H.J. Han,

H.J. Han

Departments of Dermatology and Pathology, Kang-Nam Sacred Heart Hospital, College of Medicine, Hallym University, 948-1 Daelim 1-dong, Youngdeungpo-Gu, Seoul 150-950, Korea

Search for more papers by this author

C.H. Lee,

C.H. Lee

Departments of Dermatology and Pathology, Kang-Nam Sacred Heart Hospital, College of Medicine, Hallym University, 948-1 Daelim 1-dong, Youngdeungpo-Gu, Seoul 150-950, Korea

Search for more papers by this author

H.K. Ahn,

H.K. Ahn

Departments of Dermatology and Pathology, Kang-Nam Sacred Heart Hospital, College of Medicine, Hallym University, 948-1 Daelim 1-dong, Youngdeungpo-Gu, Seoul 150-950, Korea

Search for more papers by this author

C.W. Park,

C.W. Park

Departments of Dermatology and Pathology, Kang-Nam Sacred Heart Hospital, College of Medicine, Hallym University, 948-1 Daelim 1-dong, Youngdeungpo-Gu, Seoul 150-950, Korea

Search for more papers by this author

B.H. Lee,

B.H. Lee

Departments of Dermatology and Pathology, Kang-Nam Sacred Heart Hospital, College of Medicine, Hallym University, 948-1 Daelim 1-dong, Youngdeungpo-Gu, Seoul 150-950, Korea

Search for more papers by this author

H.J. Han,

H.J. Han

Departments of Dermatology and Pathology, Kang-Nam Sacred Heart Hospital, College of Medicine, Hallym University, 948-1 Daelim 1-dong, Youngdeungpo-Gu, Seoul 150-950, Korea

Search for more papers by this author

C.H. Lee,

C.H. Lee

Departments of Dermatology and Pathology, Kang-Nam Sacred Heart Hospital, College of Medicine, Hallym University, 948-1 Daelim 1-dong, Youngdeungpo-Gu, Seoul 150-950, Korea

Search for more papers by this author

H.K. Ahn,

H.K. Ahn

Departments of Dermatology and Pathology, Kang-Nam Sacred Heart Hospital, College of Medicine, Hallym University, 948-1 Daelim 1-dong, Youngdeungpo-Gu, Seoul 150-950, Korea

Search for more papers by this author

First published: 22 May 2005

https://doi.org/10.1111/j.1365-2133.2005.06474.x

Citations: 43

Chun Wook Park.
E-mail: [email protected]

Conflicts of interest: None declared.

Share a link

Email
Wechat
Bluesky

Summary

Background There is a lack of studies on the effect of tacrolimus on eosinophils and related molecules including eotaxin, CCR3, RANTES and interleukin (IL)-5.

Objectives To investigate the effects of tacrolimus on in vivo eosinophil counts and on the related molecules eotaxin, CCR3, RANTES and IL-5 in patients with atopic dermatitis (AD).

Methods Lesional skin specimens and sera were obtained from 15 patients with AD and from 15 normal controls. For 8 weeks, the patients with AD applied 0·03% tacrolimus ointment to all affected areas twice daily. Blood sampling and skin biopsies were then repeated. We evaluated serum eotaxin and IL-5 levels, and tissue eotaxin, CCR3, RANTES and IL-5 levels. Additionally, tissue levels of eotaxin and CCR3 mRNA were measured.

Results After treatment with topical tacrolimus twice daily for 8 weeks, significant decreases were found in serum IL-5 levels, immunoreactive cell counts of eotaxin, IL-5, CCR3 and RANTES in AD skin, and tissue eosinophil counts. However, the change in the serum eosinophil count was not statistically significant, and mRNA levels of eotaxin and CCR3 were not decreased significantly after treatment.

Conclusions Topical tacrolimus reduces the number of eosinophils in tissue and suppresses the expression of eotaxin, CCR3, RANTES and IL-5 related to proliferation, recruitment, activation and survival of eosinophils.

References

1 Novak N, Bieber T, Leung DYM. Immune mechanism leading to atopic dermatitis. J Allergy Clin Immunol 2003; 112: 128–39S.DOI: 10.1016/j.jaci.2003.09.032
10.1016/j.jaci.2003.09.032
CAS PubMed Google Scholar
2 Meagher LJ, Wines NY, Cooper AJ. Atopic dermatitis: review of immunopathogenesis and advances in immunosuppressive therapy. Australas J Dermatol 2002; 43: 247–54.DOI: 10.1046/j.1440-0960.2002.00610.x
10.1046/j.1440-0960.2002.00610.x
PubMed Google Scholar
3 Won CH, Seo PG, Park YM et al. A multicenter trial of the efficacy and safety of 0·03% tacrolimus ointment for atopic dermatitis in Korea. J Dermatol Treat 2003; 14: 1–5.
Google Scholar
4 Reitamo S, Wollenberg A, Schopf E et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol 2000; 136: 999–1006.DOI: 10.1001/archderm.136.8.999
10.1001/archderm.136.8.999
CAS PubMed Web of Science® Google Scholar
5 Kang S, Lucky AW, Pariser D et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001; 44 (Suppl.): 58–64.DOI: 10.1067/mjd.2001.109812
10.1067/mjd.2001.109812
CAS PubMed Web of Science® Google Scholar
6 Cheer SM, Plosker GL. Tacrolimus ointment. A review of its therapeutic potential as a topical therapy in atopic dermatitis. Am J Clin Dermatol 2001; 2: 389–402.
10.2165/00128071-200102060-00005
CAS PubMed Google Scholar
7 Shozo S, Yasuyuki H, Natuki S et al. Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system (comparison with steroids). Int Immunopharmacol 2001; 1: 1219–26.DOI: 10.1016/S1567-5769(01)00059-5
10.1016/S1567-5769(01)00059-5
PubMed Web of Science® Google Scholar
8 Leiferman KM, Plager DA, Gleich GJ. Eosinophils and atopic dermatitis. In: Atopic Dermatitis ( T Bieber, DYM Leung, eds). New York: Marcel Dekker, 2002; 327–55.
10.3109/9780203908877-17
Google Scholar
9 Simon D, Braathen LR, Simon HU. Eosinophils and atopic dermatitis. Allergy 2004; 59: 561–70.DOI: 10.1111/j.1398-9995.2004.00476.x
10.1111/j.1398-9995.2004.00476.x
CAS PubMed Web of Science® Google Scholar
10 Barnes PJ. Molecular mechanisms of corticosteroids in allergic diseases. Allergy 2001; 56: 928–36.
10.1034/j.1398-9995.2001.00001.x
CAS PubMed Web of Science® Google Scholar
11 Mori A, Kaminuma O, Suko M et al. Two distinct pathways of interleukin-5 synthesis in allergen-specific human T-cell clones are suppressed by glucocorticoids. Blood 1997; 89: 2891–900.
10.1182/blood.V89.8.2891
CAS PubMed Web of Science® Google Scholar
12 Meagher LC, Cousin JM, Seckl JR et al. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol 1996; 156: 4422–8.
10.4049/jimmunol.156.11.4422
CAS PubMed Web of Science® Google Scholar
13 Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 1980; 92 (Suppl.): 44–7.
Google Scholar
14 Hanifin JM, Thurston M, Omoto M et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol 2001; 10: 11–18.DOI: 10.1034/j.1600-0625.2001.100102.x
10.1034/j.1600-0625.2001.100102.x
CAS PubMed Web of Science® Google Scholar
15 Beltrani VS, Boguneiwicz M. Atopic dermatitis. Dermatol Online J 2003; 9: 1.
PubMed Google Scholar
16 Novak N, Bieber T, Leung DYM. Immune mechanisms leading to atopic dermatitis. J Allergy Clin Immunol 2003; 112 (Suppl.): 128–39.DOI: 10.1016/j.jaci.2003.09.032
10.1016/j.jaci.2003.09.032
CAS PubMed Google Scholar
17 Hanifin JM. Atopic dermatitis: new therapeutic consideration. J Am Acad Dermatol 1991; 24: 1097–101.
10.1016/0190-9622(91)70165-X
CAS PubMed Web of Science® Google Scholar
18 Kapp A. The role of eosinophils in the pathogenesis of atopic dermatitis: eosinophil granule proteins as markers of disease activity. Allergy 1993; 48: 1–5.
10.1111/j.1398-9995.1993.tb02167.x
PubMed Web of Science® Google Scholar
19 Cheng JF, Ott NL, Peterson EA et al. Dermal eosinophils in atopic dermatitis undergo cytolytic degeneration. J Allergy Clin Immunol 1997; 99: 683–92.
10.1016/S0091-6749(97)70031-9
CAS PubMed Web of Science® Google Scholar
20 Kristjansson S, Shimizu T, Strannegard IL, Wennergren G. Eosinophil cationic protein, myeloperoxidase and tryptase in children with asthma and atopic dermatitis. Pediatr Allergy Immunol 1994; 5: 223–9.
10.1111/j.1399-3038.1994.tb00244.x
CAS PubMed Google Scholar
21 Pucci N, Lombardi E, Novembre E et al. Urinary eosinophil protein X and serum eosinophil cationic protein in infants and young children with atopic dermatitis: correlation with disease activity. J Allergy Clin Immunol 2000; 105: 353–7.DOI: 10.1016/S0091-6749(00)90087-3
10.1016/S0091-6749(00)90087-3
CAS PubMed Web of Science® Google Scholar
22 Ott NL, Gleich GJ, Peterson EA et al. Assessment of eosinophil and neutrophil participation in atopic dermatitis: comparison with the IgE-mediated late phase reaction. J Allergy Clin Immunol 1994; 94: 120–8.
10.1016/0091-6749(94)90078-7
CAS PubMed Web of Science® Google Scholar
23 Simon HU. Eosinophil apoptosis—pathophysiologic and therapeutic implications. Allergy 2000; 55: 910–15.DOI: 10.1034/j.1398-9995.2000.055010910.x
10.1034/j.1398-9995.2000.055010910.x
CAS PubMed Web of Science® Google Scholar
24 Giembycz MA, Lindsay MA. Pharmacology of the eosinophil. Pharmacol Rev 1999; 51: 213–340.
CAS PubMed Web of Science® Google Scholar
25 Rankin SM, Conroy DM, Williams TJ. Eotaxin and eosinophil recruitment: implications for human disease. Mol Med Today 2000; 6: 20–7.DOI: 10.1016/S1357-4310(99)01635-4
10.1016/S1357-4310(99)01635-4
Google Scholar
26 Hossny E, Aboul-Magd M, Bakr S. Increased plasma eotaxin in atopic dermatitis and acute urticaria in infants and children. Allergy 2001; 56: 996–1002.DOI: 10.1034/j.1398-9995.2001.00169.x
10.1034/j.1398-9995.2001.00169.x
CAS PubMed Web of Science® Google Scholar
27 Morita E, Kameyoshi Y, Hiragun T et al. The C-C chemokines, RANTES and eotaxin, in atopic dermatitis. Allergy 2001; 56: 194–5.DOI: 10.1034/j.1398-9995.2001.056002194.x
10.1034/j.1398-9995.2001.056002194.x
CAS PubMed Web of Science® Google Scholar
28 Trautmann A, Akdis M, Klunker S et al. Role of apoptosis in atopic dermatitis. Int Arch Allergy Immunol 2001; 124: 230–2.DOI: 10.1159/000053720
10.1159/000053720
CAS PubMed Web of Science® Google Scholar
29 Yawalkar N, Uguccioni M, Scharer J et al. Enhanced expression of eotaxin and CCR3 in atopic dermatitis. J Invest Dermatol 1999; 113: 43–8.DOI: 10.1046/j.1523-1747.1999.00619.x
10.1046/j.1523-1747.1999.00619.x
CAS PubMed Web of Science® Google Scholar
30 Schreiber SL, Crabtree GR. The mechanism of action of cyclosporine and FK506. Immunol Today 1992; 13: 136–42.DOI: 10.1016/0167-5699(92)90111-J
10.1016/0167-5699(92)90111-J
CAS PubMed Web of Science® Google Scholar
31 Sigal NH, Dumont FJ. Cyclosporin A, FK506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol 1992; 10: 519–60.
10.1146/annurev.iy.10.040192.002511
CAS PubMed Web of Science® Google Scholar
32 Kagami S, Kakinuma T, Saeki H et al. Significant elevation of serum levels of eotaxin-3/CCL26, but not of eotaxin-2/CCL24, in patients with atopic dermatitis: serum eotaxin-3/CCL26 levels reflect the disease activity of atopic dermatitis. Clin Exp Immunol 2003; 134: 309–13.DOI: 10.1046/j.1365-2249.2003.02273.x
10.1046/j.1365-2249.2003.02273.x
Google Scholar
33 Gerber BO, Zanni MP, Uguccioni M et al. Functional expression of the eotaxin receptor CCR3 in T lymphocytes co-localizing with eosinophils. Curr Biol 1997; 7: 836–43.DOI: 10.1016/S0960-9822(06)00371-X
10.1016/S0960-9822(06)00371-X
CAS PubMed Web of Science® Google Scholar
34 Kondo S, Yazawa H, Jimbow K. Reduction of serum interleukin-5 levels reflect clinical improvement in patients with atopic dermatitis. J Dermatol 2001; 28: 237–43.
10.1111/j.1346-8138.2001.tb00124.x
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume152, Issue6

June 2005

Pages 1173-1181

Tacrolimus decreases the expression of eotaxin, CCR3, RANTES and interleukin-5 in atopic dermatitis

Summary

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Tacrolimus decreases the expression of eotaxin, CCR3, RANTES and interleukin-5 in atopic dermatitis

Summary

References

Citing Literature

References

Related

Information